Needham analyst Ami Fadia reiterates Bicycle Therapeutics (NASDAQ:BCYC) with a Buy and maintains $72 price target.
Can-Fite Reports New Phase III Psoriasis Data Showing Superior Safety & Improved Efficacy Presented By KOL Dr. Papp At The 31st European Academy Of Dermatology
Dr. Papp: "The safety results on Piclidenoson and its progressive effectiveness over the study period position it as unique among the current treatment options especially given the chronic nature of psoriasis
